Ms Joubert, could you start by telling our readers over the 16 months of heading the operations here, what have been the most challenging situations as…
In Conversation
The line between research based pharmaceutical companies and generic companies is today less and less relevant, as we have seen in the past few years generic…
Mr. Godard, you previously worked in Europe for Baxter Edwards Life Sciences, what made you decide to move to South Africa in a smaller company? It…
Your professional career went back and forth between creating your own business and running a smaller and very dynamic structure and managing over a thousand of…
You were recently appointed at the head of Eli Lilly South African operations. What is the specific mission you have been given? Eli Lilly South Africa…
Yuhan is one of the largest and fastest growing pharmaceutical companies in South Korea, with a long history in the sector. In your view, what are…
South Korea has a much shorter history of clinical trials than many other advanced economies. In your view, what is the potential for South Korea’s clinical…
Mr. Zahradnik, you have long been an active member of the Czech generic drug makers’ association CAFF (Czech Association of Pharmaceutical Firms), chairing the organization. Dr.…
Since we interviewed you in 2005, there have been many changes in the market, from consolidation, an increasing generic penetration, to new healthcare reforms… How have…
After spending a large part of your career as a university professor, what drove you to create your own company, Histostem, in 2000? In 1993, I…
“ Mr. Polach, can you please begin with an introduction to CzechBio and explicate the association’s mission on this market? ”
The Aspen Group identified Latin America as a “large developing market where it can leverage its substantial intellectual property portfolio and manufacturing infrastructure”. What was the…
